1 / 6

Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023

Hemoglobinopathies Market size was valued at over USD 4 billion in 2015. High occurrence in underdeveloped nations such as Arab nations, Sub-Saharan region and South East Asia is a major growth driver.

jueekate
Download Presentation

Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemoglobinopathies Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023: Global Market Insights Inc. Fuel Cell Market size worth $25.5bn by 2024 Low Power Wide Area Network

  2. Regional Analysis of HemoglobinopathiesMarket: • Globally, incidence of thalassemia is about 0.2 million patients, whereas sickle cell anemia has higher occurrence of around 20 million. • In 2015, North America was the largest revenue generating region with around USD 1.2 billion owing to rise in R&D investments, better compensation state, and presence of high quality healthcare infrastructure. • Asia Pacific hemoglobinopathies market share is anticipated to increase at 9% CAGR due to rising patient awareness and introduction of manufactured and low cost diagnostic kits. • Sickle cell anemia is the most prevalentdisease in West Africa, with nearly 20% of people having sickle cell trait and about 2% of total babies born with a form of the disease. In many regions of Europe, hemoglobin (Hb) disorders are classified as prevalent diseases.

  3. Application Analysis of HemoglobinopathiesMarket: • Hemoglobinopathy is a group of inherited disorders caused due to abnormal production or aberration in hemoglobin structure. • Different disorders comprise sickle cell anemia, S-C and hemoglobin C disorder and various forms of thalassemia. • Originally found in the Mediterranean area and large parts of Asia and Africa, they now have presence across the globe on account of growing migration. • Most common tools/tests for diagnosis of hemoglobinopathies and thalassemia disorders are pre-implantation genetic diagnosis, genetic and blood testing, alkaline and acid gel electrophoresis, hemoglobin electrophoresis, prenatal genetic testing and HbA2 quantification by ion exchange column chromatography.

  4. Competitive Market Share of HemoglobinopathiesMarket : • Key industry players comprise Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, SangamoBioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Genetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Calgene Corporation, Invenux, Optinova Ab, and HemaQuest Pharmaceuticals. • Companies are aiming on the partnership and licensing deals for sharing the research and development platform. In 2014, SangamoBioSciences and Biogen Idec declared collaboration agreement that targeted hemoglobinopathies market therapeutics development.

  5. Browse Full Market Research Report On HemoglobinopathiesMarket @ https://www.gminsights.com/industry-analysis/hemoglobinopathies-market Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/470

  6. Stay In Touch Website: www.gminsights.com Social Media:

More Related